Healthcare
MBX Biosciences, Inc. Common Stock(MBX)
Live Price
Offline$43.03
+3.46% today
Window Change
+47.00%
Window
Jun 9, 2026 โ Jun 22, 2026
- Market Cap
- $1.00B
- Revenue Growth
- 0.0%
- EPS Growth
- -28.6%
- Dividend Yield
- 0.0%
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 9 bars ยท Jun 9, 2026 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
MBX Biosciences, Inc. Common Stock (MBX) is a Healthcare stock with a market cap of $1.00B and listed on NASDAQ. The stock last traded around $43.03 and up 47.0% across the available one-year price window (Jun 9, 2026 โ Jun 22, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -28.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -28.6%, free cash flow -47.4% with operating margin 0.0% and ROIC -26.5%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines MBX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -28.6%, with operating margin around 0.0%.
Benchmark Edge
MBX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
MBX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
MBX Max Drawdown
-4.67%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for MBX and SPY.
Company Overview
MBX Biosciences, Inc. Common Stock
NASDAQ Global Select
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
- Leadership
- Peter Kent Hawryluk
- IPO Date
- Jan 14, 2000
- Employees
- 43
- Street Address
- 11711 N. Meridian Street
- Mailing
- Carmel, IN, 46032
- Region
- Carmel, IN, US
- Reporting Currency
- USD
- Investor Line
- (317) 659-0200
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.9
Growth
- Revenue
- 0.0%
- EPS
- -28.6%
- Free Cash Flow
- -47.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -28.7%
- ROIC
- -26.5%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 24.62
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.